Amivantamab Plus Chemotherapy Reduced Risk of Disease Progression By 60% in Patients With NSCLC

Compared to chemotherapy alone, amivantamab plus chemotherapy had a better objective response rate and prolonged progression-free survival and overall survival.

Related Keywords

Saint Quentin ,Champagne Ardenne ,France ,Paris ,France General ,Nicolas Girard ,Kiran Patel ,Janssen Research Development ,European Society Of Medical Oncology ,Janssen Pharmaceutical Companies ,Versailles Saint Quentin University ,Institute Curie ,European Society ,Medical Oncology ,Janssen Research ,